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The aim of this study was to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of bortezomib plus
docetaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Forty-eight patients received up to eight 21-
day cycles of docetaxel (60–100mgm
 2 on day 1) plus bortezomib (1.0–1.5mgm
 2 on days 1, 4, 8, and 11). Pharmacodynamic
and pharmacokinetic analyses were performed in a subset of patients. Five patients experienced DLTs: grade 3 bone pain (n¼1) and
febrile neutropenia (n¼4). The MTD was bortezomib 1.5mgm
 2 plus docetaxel 75mgm
 2. All 48 patients were assessable for
safety and efficacy. The most common adverse events were diarrhoea, nausea, alopecia, asthenia, and vomiting. The most common
grade 3/4 toxicities were neutropenia (44%), and febrile neutropenia and diarrhoea (each 19%). Overall patient response rate was
29%. Median time to progression was 5.4 months. In patients with confirmed response, median time to response was 1.3 months and
median duration of response was 3.2 months. At the MTD, response rate was 38%. Pharmacokinetic characteristics of bortezomib/
docetaxel were comparable with single-agent data. Addition of docetaxel appeared not to affect bortezomib inhibition of 20S
proteasome activity. Mean alpha-1 acid glycoprotein concentrations increased from baseline at nearly all time points across different
bortezomib dose levels. Bortezomib plus docetaxel is an active combination for anthracycline-pretreated advanced/metastatic breast
cancer. The safety profile is manageable and consistent with the side effects of the individual agents.
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Anthracyclines and taxanes are widely used in treating patients
with metastatic breast cancer. In anthracycline-pretreated ad-
vanced/metastatic breast cancer, docetaxel administered once
every 3 weeks is more active than the same schedule of paclitaxel
(Jones et al, 2005). The efficacy of docetaxel as a single agent
(Nabholtz et al, 1999; Sjostrom et al, 1999; Jones et al, 2005) or in
combination with cytotoxic agents (O’Shaughnessy et al, 2002;
Chan et al, 2005) has been established in phase III trials in this
setting. The standard dose of single-agent docetaxel is 75–
100mgm
 2 every 21 days. In combination, the dose is reduced,
typically to 75mgm
 2 (Aventis Pharmaceuticals Inc, 2005). Dose
reduction potentially reduces efficacy; therefore, careful identifica-
tion of dosing regimens that provide acceptable safety profiles
without compromising efficacy is essential.
Combining agents with unique modes of action may improve
outcomes and overcome chemoresistance without significantly
increasing toxicity. Docetaxel acts by disrupting the microtubular
network essential for cellular functions (Bissery et al, 1995;
Eisenhauer and Vermorken, 1998). Bortezomib, which is approved
for treating multiple myeloma and mantle cell lymphoma patients
who have received at least one prior therapy (Kane et al, 2006),
acts by inhibiting the 26S proteasome, the degradative enzyme
complex involved in the catabolism of numerous intracellular
regulatory proteins, including NF-kB (nuclear factor-kB)-inhibitor
IkBa, p53, p21, and p27 (Adams, 2002; Cusack, 2003; Lenz, 2003;
Boccadoro et al, 2005). Malignancies with high concentrations of
activated NF-kB, such as breast cancer, are logical targets for
agents that interrupt this pathway (Orlowski and Dees, 2003).
Mutations in the tumour suppressor gene p53 occur in 20–40% of
sporadic breast cancers (Osin and Lakhani, 1999) and are
associated with a poor prognosis (Pharoah et al, 1999; Overgaard
et al, 2000) and poor response to treatment with certain
chemotherapeutic and hormonal agents (Berns et al, 2000;
Kandioler-Eckersberger et al, 2000). The cyclin-dependent kinase
inhibitors p21 and p27 also play important roles in breast cancer
(Osin and Lakhani, 1999), supporting the investigation of
bortezomib in breast malignancies.
Bortezomib has demonstrated cytotoxic activity in breast, lung,
pancreatic, prostate, and head and neck tumour models in vivo
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et al, 2001; Nawrocki et al, 2002; Williams et al, 2003; Ikezoe et al,
2004). Preliminary in vitro and in vivo studies in a range of solid
tumours demonstrated an additive antitumour effect of bortezo-
mib with standard cytotoxic agents, including docetaxel (Gumerlock
et al, 2002, 2004; Mack et al, 2003; Nawrocki et al, 2004;
Farneth et al, 2005). Bortezomib 1mgkg
 1 combined with
docetaxel 5mgkg
 1 was active in pancreatic xenograft models
(Nawrocki et al, 2004). Interestingly, sequential administration led
to greater tumour growth inhibition than with either agent alone
(Gumerlock et al, 2004). Preclinical studies in prostate and lung
cancer models indicated that the sequence docetaxel-bortezomib
was more effective than bortezomib-docetaxel (Gumerlock et al,
2002; Farneth et al, 2005). A possible explanation is that
bortezomib promotes cell cycle arrest before the M phase,
consequently interfering with docetaxel-induced apoptosis
(Nawrocki et al, 2004). Additionally, in vitro studies have shown
that docetaxel is extensively plasma protein-bound, especially to
alpha-1 acid glycoprotein (AAG), albumin, and lipoproteins
(Aventis Pharmaceuticals Inc, 2005). As AAG is an acute-phase
protein that may be elevated by IL (interleukin)-6, which is
inhibited by bortezomib (Hideshima et al, 2001), bortezomib may
decrease AAG concentrations and improve docetaxel efficacy.
In clinical studies in patients with solid tumours, bortezomib/
docetaxel combination therapy demonstrated encouraging activity,
and the side effects were predictable and manageable (Meluch
et al, 2005; Fanucchi et al, 2006; Lara et al, 2006; Dreicer et al,
2007). There is no evidence of a drug interaction between
bortezomib and docetaxel (Messersmith et al, 2006).
Based on the known single-agent antitumour activity of
bortezomib and docetaxel, and their additive efficacy in preclinical
models, complementary mechanisms of action (Nawrocki et al,
2004), different toxicity profiles, and feasibility in clinical studies
in various solid tumours, we conducted the current study to
explore the potential of bortezomib/docetaxel combination ther-
apy in patients with advanced/metastatic breast cancer. Our
primary aim was to identify the most appropriate regimen for
further evaluation.
PATIENTS AND METHODS
Study objectives
The primary objective was to establish the dose-limiting toxicity
(DLT) and maximum tolerated dose (MTD) of bortezomib/
docetaxel combination therapy in patients with advanced and/or
metastatic breast cancer that had previously been treated with
anthracyclines. Secondary objectives were to assess tumour
response rate (complete response (CR), partial response (PR), or
stable disease (SD)), time to response, duration of response, and
time to disease progression (TTP); evaluate disposition profiles of
docetaxel and bortezomib administered in combination using
pharmacokinetic analyses; evaluate pharmacodynamic properties
of bortezomib in combination with docetaxel using 20S protea-
some inhibition assay (Lightcap et al, 2000); and investigate the
possible influence of bortezomib/docetaxel combination treatment
on serum concentrations of AAG.
Eligibility
All study participants provided written, informed consent. Patients
who had advanced/metastatic breast cancer, had received at least
one anthracycline-containing regimen, were aged X18 years, and
had a Karnofsky Performance Status X80% (ECOG 0–1) were
considered eligible. Prior treatment with endocrine or biologic
agents was permitted. Patients were excluded if they had
previously received docetaxel or paclitaxel as adjuvant treatment
within the previous year or for metastatic disease at any time;
radiotherapy to 435% of bone marrow (e.g., pelvic radiation),
major surgery, or chemotherapy within 4 weeks of enrollment;
nitrosoureas within 6 weeks or antibody therapy within 8 weeks of
enrollment; or high-dose chemotherapy and peripheral blood stem
cell transplantation at any time. Patients were excluded if they had
grade X1 peripheral neuropathy; abnormal laboratory values
within 2 weeks of enrollment; history of severe hypersensitivity
reaction to docetaxel; not recovered from all toxic effects (except
alopecia) of previous chemotherapy, radiotherapy, or antibody
therapy. The following were prohibited during the study treatment:
any investigational agent other than bortezomib, haematopoietic
growth factors during the first cycle (except for haematologic DLT,
or continued erythropoietin for pre-existing anaemia), immuno-
therapeutic agents, steroids (except dexamethasone), chemo-
therapeutic agents other than docetaxel, radiotherapy, or surgery
for cancer.
Study design
This prospective, phase I/II, open-label dose-escalation study was
conducted at six centers in Europe (Belgium, Spain, UK) in
accordance with the International Conference on Harmonisation
for Good Clinical Practice. The protocol and informed consent
were approved by the Institutional Review Board at each clinical
site before study initiation.
Each 3-week treatment cycle consisted of docetaxel (Taxotere
s;
Sanofi-Aventis, Paris, France) infusion on day 1 and bortezomib
(Velcade
s; Millennium Pharmaceuticals Inc., Cambridge, MA, USA
and Johnson & Johnson Pharmaceuticals, Rariman, NY, USA,
Research and Development, L.L.C) injections on days 1, 4, 8,
and 11. Bortezomib was administered 1h after docetaxel.
Treatment comprised eight cycles. Docetaxel was administered at
doses of 60, 75, or 100mgm
 2 with standard oral dexamethasone
premedication (six 8-mg doses administered the night before,
morning of, immediately before, evening after, and morning and
evening of day 2 after each docetaxel infusion). Bortezomib doses
were 1.0, 1.3, or 1.5mgm
 2, based on tolerability and efficacy in
heavily pretreated patients with solid tumours. All patients
received appropriate supportive therapy. Patients achieving a
tumour response at the end of the treatment could receive further
treatment at the investigator’s discretion. Patients with progressive
disease discontinued treatment.
Patients were evaluated for toxicities before each scheduled
study drug dose. Adverse events (AEs) were graded according to
the National Cancer Institute Common Toxicity Criteria (version
2.0). The following AEs during the first cycle were considered
DLTs: platelet count p25 10
9l
 1; febrile neutropenia (absolute
neutrophil count [ANC]o1 10
9l
 1 with temperature X38.51C);
ANCo0.5 10
9l
 1 for days 1–7, or o0.2 10
9l
 1 without fever
for X7 days starting on or after day 8; any other grade 4
haematologic toxicity; grade 2 peripheral neuropathy; any grade 3
or 4 non-haematologic toxicity (except inadequately treated
nausea, vomiting, and diarrhoea). In patients experiencing grade
4 haematologic or grade 3/4 non-haematologic toxicity, the start of
the next cycle was delayed for up to 2 weeks or bortezomib therapy
was interrupted for up to 2 weeks until toxicity returned to
baseline or better. Treatment was re-initiated at a reduced dose
(25% dose reduction of the drug considered by the investigator to
have caused the toxicity). A maximum of two dose reductions for
each drug was recommended. If toxicity did not resolve, the
patient was excluded from further study.
Doses of both agents were reduced if patients experienced grade
2 neuropathic pain or peripheral neuropathy. In patients with
either toxicity at grade 3 intensity or both toxicities at grade 2,
bortezomib treatment was interrupted until resolution to grade
p1, when dose was reduced, and at resolution, treatment was
continued using weekly bortezomib (days 1 and 8 only). In
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neuropathy, or both toxicities with grade 3 intensity, bortezomib
and docetaxel were discontinued.
Doses were escalated in a stepwise fashion if fewer two out of
three patients in a dose cohort experienced a DLT. The MTD was
defined as the dose below that causing DLTs in at least two out of
three patients. Up to 10 additional patients were to be enrolled at
the MTD.
Study assessments
Karnofsky Performance Status assessments, physical examina-
tions, and laboratory sampling were undertaken during screening,
during the first cycle, at the end-of-therapy visit (10 days after the
last dose of study drug), and at the end-of-study visit (3 weeks
after the end-of-therapy visit).
Lesions were assessed by CT/MRI every 6 weeks using the
Response Evaluation Criteria in Solid Tumours (Therasse et al,
2000). Response was confirmed 6 weeks later in patients with
CR/PR. Efficacy was also assessed based on the expression of
tumour marker CA15.3, Karnofsky Performance Status, and
C-reactive protein, IL-6, and AAG concentrations. Blood samples
were collected at screening, on day 1 of cycles 3, 5, and 7 (and all
odd-numbered cycles thereafter in responding patients receiving
further treatment), and at the end-of-study visit.
In patients participating in pharmacokinetic analysis, blood
samples were taken on day 1, cycle 1, to determine the plasma
concentration time profile of docetaxel and bortezomib. Samples
were collected immediately before docetaxel infusion and borte-
zomib injection and at prespecified intervals on day 1. Samples
were also taken for bortezomib pharmacokinetic analysis on day
11 of cycle 1. Whole-blood samples were taken for pharmacody-
namic analysis using 20S proteasome inhibition assay (Lightcap
et al, 2000) immediately before and 1h after bortezomib dosing on
days 1 and 11 of cycles 1 and 2, and on days 2 and 12 of cycle 1, in
a subset of patients participating in pharmacokinetic analysis.
Samples for determination of AAG concentrations were collected
at screening and before docetaxel administration on day 1 of cycles
1, 2, 4, and 6.
Statistical analysis
Statistical analyses were primarily descriptive; the aim of the study
was to establish the MTD of bortezomib/docetaxel combination
therapy. Planned enrollment was up to 70 patients.
Safety and efficacy were evaluated in all patients who received
any amount of either study drug. Patients who underwent dose
reduction were analysed in the dose group in which they were
initially treated. The MTD-evaluable population included all
patients in the dose-escalation phase with sufficient safety
assessments during cycle 1 to determine whether a DLT occurred.
Patients were excluded from the MTD-evaluable population if they
had discontinued during cycle 1 for reasons other than DLTs or
had received alternate antineoplastic therapies during that period.
RESULTS
Patient characteristics and disposition
Forty-eight patients were enrolled (47 females and 1 male); all
received at least one dose of docetaxel or bortezomib. Patient
characteristics are summarised in Table 1 (sites of metastases at
study entry: bone (n¼23), liver (n¼12), lung (n¼4), skin and
soft tissues (n¼8), nodes (n¼6), and others (n¼8)). The median
duration of treatment was 95 days (range: 11–179) or 4 cycles
(range: 1–9); 12 patients (25%) completed all 8 cycles of planned
therapy.
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Table 2 summarises patients treated and DLTs observed at each
dose level. No DLTs occurred at the first two dose levels (1.0/60
and 1.0/75mgm
 2). At the 1.3/75mgm
 2 dose level, one patient
developed grade 3 bone pain, which is considered a DLT and
possibly related to an induced flare of pain associated with bone
metastases. One patient each at the 1.0/100 and 1.5/75mgm
 2 dose
levels, and two at the 1.3/100mgm
 2 dose level developed febrile
neutropenia. Consequently, the MTD was defined as bortezomib
1.5mgm
 2 plus docetaxel 75mgm
 2.
Safety
All 48 patients experienced at least 1 AE, most commonly
diarrhoea, nausea, alopecia, asthenia, and vomiting (Table 3).
Grade 3/4 AEs occurred in 37 patients (77%) and were considered
drug-related in 34 (71%) patients. The most common
grade 3/4 AEs were neutropenia, febrile neutropenia, and
diarrhoea (Table 3).
Eighteen (50%) out of the 36 patients who withdrew prematurely
had unacceptable AEs listed as the primary reason for
treatment discontinuation: 4 at the bortezomib 1.0mgm
 2 dose
level, 6 at the 1.3mgm
 2 dose level, and 8 at the 1.5mgm
 2
dose level. Events leading to discontinuation included peripheral
neuropathy (nine patients), neuralgia (four patients),
paraesthesia and diarrhoea (two patients each), and neutropenia
(one patient). Twelve patients (33%) withdrew because of
progressive disease. Dose reductions were most common in the
second and third cycles of treatment (19 and 15% patients,
respectively). Two patients died on study, one due to cardiac
tamponade 3 days after the last dose of study drug and the
other from disease progression 22 days after the last dose of study
drug.
Table 2 Patients treated and DLTs observed by bortezomib and docetaxel dose level
Bortezomib (mgm
 2) Docetaxel (mgm
 2) Treated n MTD evaluable
a n DLT
1.0 60 3 3 —
1.0 75 3 3 —
1.0 100 11 7
b Febrile neutropenia (n¼1)
1.3 75 11 10
c Grade 3 bone pain (n¼1)
1.5 75 16 6
d Febrile neutropenia (n¼1)
1.3 100 4 4 Febrile neutropenia (n¼2)
Total 48 33
MTD¼maximum tolerated dose; DLT¼dose-limiting toxicity.
aThe MTD-evaluable population included all patients in the dose-escalation phase with sufficient safety
assessments during cycle 1 to determine whether a DLT occurred.
bThree patients did not complete cycle 1 of treatment, and one patient was excluded due to pre-existing
peripheral neuropathy.
cOne patient had study drug held in cycle 1 and was not used in the determination of MTD.
dTen additional patients enrolled following determination of
dose level as MTD.
Table 3 Percentage of patients experiencing the most common AEs (all grades; X25% of all patients) and grade 3 or 4 AEs (X5% of all patients)
Bortezomib/docetaxel doses (mgm
 2dose
 1)
1.0/60 n¼3 1.0/75 n¼3 1.0/100 n¼11 1.3/75 n¼11 1.3/100 n¼4 1.5/75 n¼16 Total n¼48
AE (all grades)
Diarrhoea 100 67 73 82 100 75 79
Nausea 100 67 64 73 50 56 65
Alopecia 33 67 55 64 75 50 56
Asthenia 33 67 55 82 50 44 56
Vomiting 67 33 36 82 25 50 52
Neutropenia 100 67 45 55 25 38 48
Myalgia 67 100 45 45 50 31 46
Anorexia 33 33 27 73 75 31 44
Peripheral neuropathy 0 67 36 64 50 31 42
Dysgeusia 33 67 45 64 50 13 40
Paresthesia 0 67 36 64 50 25 40
Fatigue 67 33 36 27 50 31 35
Arthralgia 67 67 27 45 25 19 33
Conjunctivitis 0 67 55 18 50 13 29
Headache 67 33 36 27 25 19 29
Constipation 33 0 27 45 25 19 27
Pyrexia 0 33 27 27 25 31 27
Mucosal inflammation 0 33 36 27 25 19 25
Neuralgia 0 33 36 36 25 13 25
AE (grade 3/4)
Neutropenia 100 33 45 55 25 31 44
Febrile neutropenia 0 0 18 18 50 19 19
Diarrhoea 33 0 18 27 25 13 19
Peripheral neuropathy 0 0 9 9 0 19 10
Leukopenia 0 33 27 0 0 6 10
Asthenia 0 33 0 18 0 6 8
Fatigue 0 0 0 0 25 13 6
Neuralgia 0 0 0 0 25 13 6
AEs¼adverse events.
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Overall, 29% (14 out of 48) patients achieved a confirmed PR and
56% (27 out of 48) achieved SD. There were no CRs. At MTD (1.5/
75mgm
 2), 38% (6 out of 16) patients achieved a PR, with an
overall clinical benefit (PRþSD) rate of 75% (12 out of 16 patients;
Table 4).
Among 14 patients achieving confirmed PR, median time to
response was 39 days (1.3 months) and median duration of
response was 96.5 days (3.2 months). Among 27 patients achieving
SD, median duration of disease stabilisation was 100.0 days (3.3
months). Median TTP for all patients was 164 days (5.4 months).
Data are shown by bortezomib dose level in Table 4.
Pharmacokinetics
Bortezomib plasma profiles exhibited an initial rapid distribution
phase followed by a slower elimination phase, demonstrating
apparent multi-exponential decay characteristics, similar to those
reported previously. Bortezomib was eliminated from plasma with
similar terminal half-lives across dose levels, with mean values of
15–18h following the first dose in patients with measurable
plasma concentrations at 24h post-dose (Table 5). Pharmaco-
kinetic characteristics of bortezomib/docetaxel were comparable
with single-agent data (Millennium Pharmaceuticals Inc.; Rosing
et al, 2000).
Pharmacodynamics
In total, 33 patients provided whole-blood samples for measure-
ment of 20S proteasome inhibition at baseline. Inhibition of
proteasome activity was greatest at 1h post-dose (46.14–88.80%).
Immediately prior to the dose on day 11, percent inhibition was
10.93–51.18%. Percent inhibition was greater in cycle 2 than cycle
1 for all dose groups. Coadministration of docetaxel with
bortezomib did not appear to affect 20S proteasome inhibition
by bortezomib. The degree of inhibition observed is similar to that
observed in studies of bortezomib monotherapy (Aghajanian et al,
2002; Orlowski et al, 2002; Blaney et al, 2004; Papandreou et al,
2004; Hamilton et al, 2005).
Limited blood samples were collected for IL-6 and CRP analysis.
Therefore, no analyses of these data were conducted. Mean AAG
concentrations increased from baseline for nearly all time points
across all three bortezomib dose levels (Figure 1).
DISCUSSION
In this phase I/II study in patients with pretreated advanced/
metastatic breast cancer, the MTD was bortezomib 1.5mgm
 2 on
days 1, 4, 8, and 11, plus docetaxel 75mgm
 2 on day 1 of a 21-day
cycle. The DLTs were bone pain and febrile neutropenia. The
bortezomib dose was slightly higher than the approved 1.3mgm
 2
on the same schedule, but similar to that identified in phase I
studies evaluating single-agent bortezomib administered on the
same schedule (Aghajanian et al, 2002; Dy et al, 2005). Slightly
higher doses were tolerated when bortezomib was administered
weekly (Papandreou et al, 2004) or on days 1 and 4 every 14 days
(Hamilton et al, 2005). In other combination dose-escalation
studies in advanced non-small-cell lung cancer and other
refractory solid tumours (Lara et al, 2006), MTDs were bortezomib
1.0mgm
 2 plus docetaxel 75mgm
 2 on the same schedule, and
bortezomib 0.8mgm
 2 twice weekly for 2 weeks plus docetaxel
25mgm
 2 on days 1 and 8 of a 21-day cycle (Messersmith et al,
2006). The docetaxel dose in our study is consistent with that used
in combination with chemotherapeutic agents in anthracycline-
pretreated breast cancer (O’Shaughnessy et al, 2002; Chan et al,
2005).
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observed in phase II studies in other solid tumours evaluating
bortezomib alone (Shah et al, 2004; Maki et al, 2005) or in
combination with docetaxel (Meluch et al, 2005; Fanucchi et al,
2006; Dreicer et al, 2007). The most common grade 3/4 toxicities
were neutropenia, febrile neutropenia, diarrhoea, and peripheral
neuropathy. Dose modifications were implemented to try and
prevent evolution of neurotoxicity and worsening of existing
symptoms. Nevertheless, in these heavily pretreated patients, 15
patients discontinued treatment due to neurological complaints, a
known side effect of bortezomib and, to a lesser extent, docetaxel.
The high incidence of neutropenia was expected given the typically
high incidence of neutropenia and febrile neutropenia with single-
agent docetaxel (Nabholtz et al, 1999; O’Shaughnessy et al, 2002)
and the partially overlapping side-effect profiles of the two agents.
Supportive therapies and strategies for side-effect management can
prevent worsening of these symptoms, thereby avoiding treatment
delays or discontinuations (Colson et al, 2004). Notably, bortezo-
mib-associated neutropenia has been shown to be transient and
reversible (Lonial et al, 2005); consistent with this, only one patient
discontinued the study drug due to neutropenia.
Bortezomib/docetaxel combination treatment demonstrated
antitumour activity. The response rate was 29% and median TTP
was 5.4 months. These data are similar to those reported for
docetaxel (75mgm
 2) in combination with either gemcitabine or
capecitabine, which have been compared in a phase III trial (Chan
et al, 2005). Recent studies have shown response rates of 62.5%
with docetaxel plus cisplatin (Lin et al, 2007) and 50% with
docetaxel plus epirubicin (Hainsworth et al, 2006). The 38%
response rate at the MTD compares favourably with docetaxel and
paclitaxel administered as single agents in anthracycline-pre-
treated metastatic breast cancer: in a recent study comparing
docetaxel and paclitaxel, response rates were 32 vs 25%, and
median TTP was 5.7 vs 3.6 months, respectively (Jones et al, 2005).
The activity demonstrated in the present study does not appear to
arise from the mechanism proposed, by which bortezomib reduces
AAG concentrations through inhibition of IL-6 and consequently
increases docetaxel efficacy, as mean AAG concentrations in-
creases from baseline at nearly all time points across bortezomib
dose levels. Other cellular and molecular effects of bortezomib may
be involved; recently published results demonstrating its differ-
ential effects in breast cancer cells may be relevant in designing
mechanism-based combination treatments (Codony-Servat et al,
2006).
Bortezomib has been studied in combination with trastuzumab
in HER2-positive breast cancer cell lines (Cardoso et al, 2006).
Although its value in HER2-postive cells is well established, the
response rate with single-agent trastuzumab in metastatic breast
cancer is o40% (Vogel et al, 2002). A preclinical study in four cell
lines demonstrated that bortezomib acts synergistically to increase
the effect of trastuzumab in HER2-positive cells (Cardoso et al,
2006). The potential clinical application of this combination is
currently under investigation in a phase I trial. Additionally, a
phase II study is underway to investigate bortezomib plus
pegylated liposomal doxorubicin in patients with anthracycline-
pretreated metastatic breast cancer.
The baseline characteristics of patients in the present study were
typical of patients with anthracycline-pretreated advanced/meta-
static breast cancer. The p53 and estrogen receptor status were not
recorded but may be of interest in future trials, as in vitro studies
suggest proteasome inhibition is at least partially dependent on
the p53 status in breast cancer (MacLaren et al, 2001), and
Table 5 Pharmacokinetic parameters of bortezomib and docetaxel by dose level
All values shown as mean (%CV)
Day C0 (ngml
 1) AUC0–t (hngml
 1) AUC0–N N (hngml
 1) T1
2,z (h) T1
2,z 24-h (h) CL (lh
 1) Vss (l) Vz (l)
Bortezomib dose (mgm
 2)
1.0 (n¼5) 1 208 (34) 43.0 (38) 54.6 (31) 9.15 (64) 15.1 (n¼2) 33.7 (30) 222 (75) 408 (63)
1.3 (n¼3) 1 137 (54) 35.5 (31) 49.0 (28) 14.2 (47) 18.1 (n¼2) 51.0 (38) 596 (45) 924 (26)
1.5 (n¼8) 1 268 (71) 69.0 (43) 85.3 (51) 6.9 (99) 17.8 (n¼2) 36.9 (57) 209 (68) 282 (77)
1.0 (n¼5) 11 552 (148) 112 (32) 133 (24) 12.2 (32) 14.3 (n¼4) 13.5 (25) 151 (49) 237 (46)
1.3 (n¼3) 11 237 (59) 90.5 (27) 111 (18) 12.2 (73) 17.1 (n¼2) 21.0 (11) 237 (96) 374 (78)
1.5 (n¼6) 11 153 (41) 103 (25) 161 (31) 23.6 (36) 23.6 16.0 (23) 391 (47) 538 (42)
Docetaxel dose (mgm
 2)
Cmax (ngml
 1) AUC0–t (hngml
 1) AUC0–N N (hngml
 1) T1
2,z (h) T1
2,z 24-h (h) CL (lh
 1) Vss (l) Vz (l)
75 (n¼7) 1 1620 (38) 1704 (50) 1847 (54) 10.4 (86) 17.6 (n¼3) 85.2 (47) 180 (72) 920 (33)
100 (n¼6) 1 2522 (51) 2547 (36) 2731 (34) 15.0 (42) 17.4 (n¼5) 69.6 (31) 372 (85) 1514 (55)
C0¼back-extrapolated time 0 plasma drug concentration (bortezomib alone); Cmax¼observed maximum plasma drug concentration (docetaxel alone); AUC0 t¼area under
plasma concentration time curve from time 0 to last time point with measurable drug concentration; AUC0 N¼area under plasma concentration time curve extrapolated to
infinity; T1
2,z¼apparent plasma half-life; T1
2,z (24-h)¼apparent plasma half-life in patients with measurable plasma concentrations at 24h post-dose; CL¼total body clearance;
CV¼coefficient of variance; Vss¼volume of distribution at steady state; Vz¼apparent volume of distribution in terminal elimination phase.
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Figure 1 Mean change from baseline in alpha-1 acid glycoprotein
concentrations by bortezomib dose level during the study. The number of
patients available for each analysis are shown above or below each column;
notably, the significant decrease from baseline seen at cycle 6, day 1, in the
bortezomib 1.5mgm
 2 group arises from evaluation of data from only one
patient.
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system is associated with greater bortezomib antitumour activity
(Tapia et al, 2005).
In conclusion, the study demonstrated that bortezomib and
docetaxel combination therapy is feasible, tolerable, and active in
anthracycline-pretreated metastatic breast cancer.
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